Linda Ohrmund

TL;DR: Patients with low IFX trough levels at week 14 are at risk for ATI formation and IFX discontinuation, and it is recommended to measure IFX crest levels atWeek 14 and at time of LOR to rule out sustained ATI.

TL;DR: The development of ATI increases the probability of active disease even at low concentrations and in the presence of a therapeutic concentration of drug during infliximab maintenance therapy.

TL;DR: A non-radiolabeled homogeneous mobility shift assay (HMSA) to measure the antibodies-to-infliximab (ATI) and IFX levels in serum samples that may be applied to other protein-based drugs to accurately detect serum drug and anti-drug antibody levels.

TL;DR: Evidence that drug and anti-drug antibody levels are important determinants of patient response to therapy is presented, with validation and application of the homogeneous mobility shift assay method for the measurement of adalimumab and human antibodies-to-adalimumab in serum samples from patients who have lost response to adAlimumab treatment.

TL;DR: Antibodies to infliximabmay be transient and can disappear after dose optimisation and that patients may recapture response.